Drug Type Chemical drugs |
Synonyms |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors), SOAT2 inhibitors(sterol O-acyltransferase 2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization PRD Therapeutics, Inc.Startup |
Active Organization PRD Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Homozygous familial hypercholesterolemia | Preclinical | JP | PRD Therapeutics, Inc.Startup | 06 Sep 2024 |
Nonalcoholic Steatohepatitis | Preclinical | JP | PRD Therapeutics, Inc.Startup | 06 Sep 2024 |